Article in Journal of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
9 authors.
John V Dzimianski *Department of Biomolecular Engineering, University of California Santa Cruz, Santa Cruz, California, USA.
Kaito A Nagashima *Center for Vaccines and Immunology, University of Georgia, Athens, Georgia, USA.ORCID 0000-0002-7501-6651
Joseph M CruzDepartment of Biomolecular Engineering, University of California Santa Cruz, Santa Cruz, California, USA.
Giuseppe A SauttoFlorida Research and Innovation Center, Cleveland Clinic, Port St. Lucie, Florida, USA.
Sara M O'RourkeDepartment of Biomolecular Engineering, University of California Santa Cruz, Santa Cruz, California, USA.
Vitor H B SerrãoBiomolecular Cryo-Electron Microscopy Facility, University of California Santa Cruz, Santa Cruz, California, USA.
Ted M RossCenter for Vaccines and Immunology, University of Georgia, Athens, Georgia, USA.ORCID 0000-0003-1947-7469
Jarrod J MousaCenter for Vaccines and Immunology, University of Georgia, Athens, Georgia, USA.ORCID 0000-0003-4709-2478
Rebecca M DuBoisDepartment of Biomolecular Engineering, University of California Santa Cruz, Santa Cruz, California, USA.ORCID 0000-0003-4185-5673
Funding
COVID Supplement - COMPONENT A OF THE COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) PROGRAM TO DESIGN AND EVALUATE INNOVATIVE INFLUENZA VACCINE APPROACHES,75N93019C00052 · NIAID · UNIVERSITY OF GEORGIA · PI ROSS, TED · 2019 to 2025
$74.6M
User Training & OutreachP30GM138396 · NIGMS · UCHICAGO ARGONNE, LLC · PI ROBERT F. FISCHETTI, JANET L. SMITH · 2020 to 2026
$34.3M
ChimeraX -- Next Generation Visualization and Analysis Software for Multiscale ModelingR01GM129325 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FERRIN, THOMAS E · 2018 to 2025
$5.2M
High-Speed High-Sensitivity Detector for X-ray Micro-Crystallography at GM/CA@APSS10OD012289 · OD · UNIVERSITY OF CHICAGO · PI FISCHETTI, ROBERT F. · 2014 to 2014
$2.0M
Therapeutic antibodies to treat Pneumocystis pneumonia in a nonhuman primate model of HIV infectionK01OD026569 · OD · UNIVERSITY OF GEORGIA · PI MOUSA, JARROD · 2018 to 2020
$1.0M
Linux cluster for near atomic resolution single particle cryo-EMS10OD020054 · OD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHENG, YIFAN · 2015 to 2015
$456k
An Octet Bio-layer Interferometer for Macromolecular Interaction Studies at UCSCS10OD027012 · OD · UNIVERSITY OF CALIFORNIA SANTA CRUZ · PI RUBIN, SETH MICHAEL · 2019 to 2019
Influenza virus infections are an ongoing seasonal disease burden and a persistent pandemic threat. Formulating successful vaccines remains a challenge due to accumulating mutations in circulating strains, necessitating the development of innovative strategies to combat present and future viruses. One promising strategy for attaining greater vaccine effectiveness and longer-lasting protection is the use of computationally optimized broadly reactive antigens (COBRAs). The COBRA approach involves
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Assessing the structural boundaries of broadly reactive antibody interactions with diverse H3 influenza hemagglutinin proteins. · full record | OpenQuestion